---
title: Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy
  targets in higher-grade meningioma
date: '2025-02-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39969538/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250219171046&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: SSTR2a and FAP are expressed in high-grade meningioma samples
  to a variable extent, and differences across meningioma subtypes underscore the
  need for biomarkers to improve patient selection. Spatial heterogeneity of target
  expression should be considered in radioligand therapy ...'
disable_comments: true
---
CONCLUSION: SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy ...